

EMPOWERING EMPOWERING IVES

Vi, diagnosed with HCM Avonne, diagnosed with HCM ohn, diagnosed with heart failure

©2024 CYTOKINETICS, All Rights Reserved. CYTOKINETICS® and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries Actual patients who consented to use of their name, image, and condition.

Forward-Looking Statements

This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements express or implied related Cytokinetics' research and development and commercial readiness activities, including the initiation, conduct, design, enrollment, progress, continuation, completion, timing and results of clinical trials, projections regarding growing prevalence, low survival rates and market opportunity in heart failure, hypertrophic cardiomyopathy (HCM) or heart failure with preserved ejection fraction (HFpEF); projections regarding the size of the addressable patient population for aficamten, omecamtiv mecarbil, CK-136, CK-586 or any of our other drug candidates; Cytokinetics' commercial readiness for aficamten or omecamtiv mecarbil; our ability to submit a new drug application for *aficamten* with FDA in the third quarter 2024 or a marketing authorization application with EMA in the fourth quarter 2024, the likelihood and/or timing of regulatory approval for our planned new drug application for aficamten, omecamtiv mecarbil or any future new drug application for any of our other drug candidates or the anticipated timing of any interactions with FDA, EMA or any other regulatory authorities in connection thereto; the timing of our commencement of a new phase 3 clinical trial of omecamtiv mecarbil, the timing of completion of MAPLE-HCM, ACACIA-HCM, CEDAR-HCM, or any of our other clinical trials, the efficacy or safety of aficamten, omecamtiv mecarbil, CK-136, CK-586 or any of our other drug candidates, our ability to fully enroll or to announce the results of any of our clinical trials by any particular date; the properties, potential benefits and commercial potential of aficamten, omecamtiv mecarbil, CK-136, CK-586 or any of Cytokinetics' other drug candidates, our ability to satisfy the conditions for disbursement of additional capital/loans under our agreements with Royalty Pharma, or Royalty Pharma's decision to opt-in to the further development of CK-586 for additional funding. Such statements are based on management's current expectations; but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trial results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy, the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Cytokinetics may incur unanticipated research, development and other costs or be unable to obtain financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. These forward-looking statements speak only as of the date they are made, and Cytokinetics undertakes no obligation to subsequently update any such statement, except as required by law. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission (the "SEC"). This presentation concerns drug candidates that are under clinical investigation, and which have not yet been approved by the U.S. Food and Drug Administration. These are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

Disclaimer: The assumptions used in the preparation of this presentation, although considered reasonable by us at the time of preparation, may prove to be incorrect. You are cautioned that the information is based on assumptions as to many factors and that actual results may vary from the results projected and such variations may be material. Accordingly, you should not place undue reliance on any forward-looking statements contained herein or rely on them as predictions of future events.

The trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. Certain information contained in this presentation relate to or are based on studies, publications and other data obtained from third-party sources as well as our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources.



Our Mission

To bring forward new medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.



Achieve regulatory approvals for drugs arising from our pipeline

Build commercial capabilities to market and sell our medicines reflective of their innovation and value

Generate sustainable and growing revenues from product sales

-• Expand our development programs

• Expand our discovery platform to muscle energetics, growth and metabolism

Be the science-driven company people want to join and partner with




Our vision is to be the leading muscle biology biopharma company that meaningfully improves the lives of patients with diseases of impaired muscle function through access to our pioneering medicines

2025 Leading with Science, Delivering for Patients

As always, we will support disease advocacy groups elevating the patient voice and live by our values of integrity, fairness and compassion in all that we do.


A Great Place to Work; Uncommon Continuity of Team





Sarcomere Directed Drug Development


The sarcomere is a molecular structure found in skeletal and cardiac muscle that enables myocytes to contract and generate force



Contractile Dysfunction Underlies Cardiac Diseases

Decreased Cardiac Contractility

- Heart Failure with Reduced Ejection Fraction (HFrEF)
- Genetic Dilated Cardiomyopathy
- Pulmonary Hypertension with Right Ventricular Heart Failure




Increased / Preserved Cardiac Contractility

- Non-obstructive Hypertrophic Cardiomyopathy (nHCM)
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Heart Failure with Preserved Ejection Fraction (certain HFpEF subsets)



A Commitment to Muscle-Directed Cardiac Medicines

Building a specialty cardiology franchise anchored by aficamten




*Pending results from MAPLE-HCM, an ongoing Phase 3 clinical trial evaluating for the potential superiority of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM. All drug candidates above are investigational products and are not approved as safe or effective for any indication.



Building a Specialty Cardiology Franchise Anchored by Aficamten

Potential patient market for specialty cardiology franchise strategy








Aficamten is an investigational agent and has not been approved for use by the U.S. Food & Drug Administration (FDA) or any regulatory agency. The safety and effectiveness of this product has not been established.

HCM Prevalence: Significant and Growing Globally


HCM prevalence estimates vary across geography and over time



Sources: 1. Husser et al 2018 doi.org/10.1371/journal.pone.0196612; 2. Hada et al 10.1016/s0002-9149(87)80107-8; 3. Codd 1989 10.1161/01.cir.80.3.564; 4. Maron et al 1995 10.1161/01.cir.92.4.785; 5. Corrado et al 1998 10.1056/NEJM199808063390602; 6. Maron et all 1999 10.1001/jama.281.7.650; 7. Nistri et al 2003 10.1016/s0002-9149(03)00132-2; 8. Zou et al 2004 10.1093/aje/kwh090; 9. Maron 2004 https://doi.org/10.1016/j.amjmed.2003.10.012; 10. Maro 2006 10.1258/004947506778604904; 11. Ng et al 2011 10.1093/europace/eur051; 12. Butzner et al 2021 10.1016/j.amjcard.2021.08.024; 13. Cardim et al 2011 10.1016/j.repc.2011.09.005



Opportunity for CMIs in Diagnosed, Symptomatic HCM Patients



Projections and forecasts for illustration.

1. Čardiovascular Research Group: CVrg Market Strategies: Heart Failure, p 48, Q4 2022; Maron BJ: et al.: Prevalence of Hypertrophic Cardiomyopathy In A General Population of Young Adults, Circulation 1995;92;785-789; Semsarian C. et al: New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy, J. Am, Coll. Cardiol. 2015; 65: 1249-1254;


2. DoF: SHA; Symphony PTD (Patient Transaction Data): Includes patients diagnosed since 2016 and having any HC transaction in the claims data universe in the last year June 2022-May 2023); 3. Lu DY et al: Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy. J. Am. Heart Assoc.2018;7:1-11 4. DoF: SHA Symphony PTD (Patient Transaction Data) includes any patients with symptoms in the last 2 years: angina, dyspnea, fatigue, palpitations, syncope, tachycardia; and/or treatments in the past 2 years: bb, ccb, dyso, ralo, Camzyos; 5. DoF Primary market research: 443 HCPs treating HCM - % of nHCM patients not considered under control with current SOC.



Aficamten: Mechanism of Action

Aficamten stabilized myosin in the released post-powerstroke state unable to hydrolyze ATP

"Fewer hands pulling on the rope"



Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.




Aficamten: Aspirational Target Profile Potential next-in-class cardiac myosin inhibitor



Aspirational information. Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.



Aficamten: Clinical Development Plan for HCM



Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.



SEQUOIA-HCM: Phase 3 Trial




Primary endpoint: Change in pVO₂ by CPET from baseline to Week 24

Secondary objectives include measuring change in KCCQ & improvement in NYHA class at week 12 and 24

Enrolled 282 patients treated with standard of care with:

- resting LVOT-G ≥30 mmHg,
- post-Valsalva LVOT-G ≥50 mmHg,
- NYHA Class II or III,
- exercise performance <80% predicted

Individualized dose up-titration based on echocardiography: LVEF ≥55%, post-Valsalva LVOT-G ≥30 mmHg



SOC: standard of care * Focused echocardiogram



SEQUOIA-HCM: Baseline Characteristics



Baseline characteristics reflect highly symptomatic patient population with reduced exercise capacity

- Significant symptom burden despite background therapy
- 61% of patients on beta-blockers
- Baseline pVO₂ reflects patient population with reduced exercise capacity

	<i>Aficamten</i> n=142	Placebo n=140		<i>Aficamten</i> n=142	Placebo n=140
Age, y	59.2 ± 12.6	59.0 ± 13.4	Background HCM therapy, n (%)		
Female sex, n (%)	56 (39.4)	59 (42.1)	Beta-blocker	86 (60.6)	87 (62.1)
Race, n (%)			Calcium channel blocker	45 (31.7)	36 (25.7)
White	108 (76.1)	115 (82.1)	Disopyramide	16 (11.3)	20 (14.3)
Geographic region, n (%)	. ,	. ,	None	19 (13.4)	22 (15.7)
		45 (22.1)	KCCQ-CSS	76 ± 18	74 ± 18
North America	49 (34.5)	45 (32.1)	NYHA FC, n (%)		
China	24 (16.9)	22 (15.7)	II	108 (76.1)	106 (75.7)
Europe and Israel	69 (48.6)	73 (52.1)	III/IV	34 (23.9)	34 (24.3)
Medical history, n (%)			Median NT-proBNP (IQR), pg/mL	818 (377–1630)	692 (335–1795)
Hypertension	75 (52.8)	70 (50.0)	Median hs-cTnl (IQR), ng/L	12.9 (7.6–33.6)	11.5 (7.7–25.0)
Paroxysmal atrial fibrillation	21 (14.8)	20 (14.3)	Echocardiographic parameters	, ,	, ,
Permanent atrial fibrillation	2 (1.4)	1 (0.7)	Valsalva LVOT-G, mmHg	82.9 ± 32	83.3 ± 33
CPET			Resting LVOT-G, mmHg	54.8 ± 27	55.3 ± 32
pVO ₂ (mL/kg/min)	18.5 (4.5)	18.6 (4.5)	LVEF, %	74.8 ± 5.5	74.8 ± 6.3
Percent of predicted pVO ₂ (%)	58 (13)	57 (12)	Maximal LV wall thickness, mm	20.7 ± 3.0	21.0 ± 3.0


Values are the mean ± SD unless otherwise indicated.



SEQUOIA-HCM: Dosing



Aficamten dose at Week 8 (end of titration)



There were no differences in age, sex, ethnicity, body mass index, or comorbidities (diabetes, hypertension or AF) between dose groups

Mean ± SD, n (%), or median (IQR)	Placebo n=140	5 mg n=5	10 mg n=18	15 mg n=49	20 mg n=68	
% per treatment group	100%	3.5%	12.7%	34.5%	47.9%	
Background HCM therapy						
Beta-blocker	87 (62.1)	5 (100.0)	10 (55.6)	31 (63.3)	40 (58.8)	
Calcium channel blocker	36 (25.7)	1 (20.0)	3 (16.7)	17 (34.7)	24 (35.3)	
Disopyramide	20 (14.3)	1 (20.0)	5 (27.8)	3 (6.1)	7 (10.3)	
Baseline study assessments						
KCCQ-CSS	74 ± 18	68 ± 26	75 ± 19	77 ± 20	75 ± 17	
NYHA class II	106 (75.7)	3 (60.0)	16 (88.9)	33 (67.3)	54 (79.4)	
NT-proBNP, pg/mL	692 (335, 1795)	1133 (992, 1475)	338 (283, 674)	871 (428, 1505)	962 (511, 2085)	
hs-cTnI, ng/L	12 (8, 25)	12 (6, 234)	10 (5, 17)	13 (7, 24)	16 (8, 38)	
pVO ₂ , mL/kg/min	18.6 ± 4.5	18.7 ± 2.9	18.6 ± 3.9	18.2 ± 4.1	18.3 ± 4.9	
Echocardiographic paramete	rs (core laborato	ry)				
LVEF at baseline, %	75 ± 6	71 ± 12	76 ± 5	75 ± 5	75 ± 5	
Peak LVOT-G at rest	55 ± 32	29 ± 13	45 ± 21	56 ± 24	58 ± 30	
Peak LVOT-G post-Valsalva	83 ± 33	51 ± 24	71 ± 29	84 ± 26	88 ± 35	
Left ventricular MWT, cm	2.10 ± 0.30	2.42 ± 0.74	1.94 ± 0.22	2.04 ± 0.26	2.11 ± 0.28	


Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established. hs-cTnl, high-sensitive cardiac troponin; IQR, interquartile range; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire-Clinical Summary score; MWT, maximal wall thickness; NT-proBNP, N-terminal pro b-type natriuretic peptide; NYHA, New York Heart Association. Coats CJ. "Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy". ESC Heart Failure 2024.



SEQUOIA-HCM: Primary Endpoint Significant improvement in exercise capacity compared to placebo



Results presented at Heart Failure 2024 and published in *NEJM*







Results consistent across all prespecified subgroups including patients receiving or not receiving background beta-blockers

	n (Afi/Plb)	Aficamten LS mean	Placebo LS mean	Me	ean difference (95% Cl)		n (Afi/Plb)	Aficamten LS mean	Placebo LS mean	Me	an difference (95% Cl)
Age <65 y	85/84	2.4	0.4	⊦∍⊸	2.0 (1.1, 2.8)	Baseline NT-proBNP (median) ≤ 788 pg/mL	66/73	2.2	0.6	⊨∎→	1.7 (0.7, 2.7)
≥65 y	57/56	0.9	-0.5	⊢-=1	1.4 (0.3, 2.5)	> 788 pg/mL	73/65	1.4	-0.6	⊢■⊣	2.0 (1.0, 2.9)
Sex						CPET Modality					
Male	86/81	2.5	0.7	⊢∎⊣	1.8 (0.9, 2.7)	Treadmill	78/77	2.5	0.2	⊢∎⊣	2.3 (1.4, 3.2)
Female	56/59	0.6	-0.8	⊢ ∎1	1.4 (0.4, 2.5)	Bicycle	64/63	0.9	-0.1	┝──╋──┤	1.0 (-0.0, 2.1)
Baseline BMI						Baseline Median pVO ₂					
<30 kg/m ²	97/94	1.9	0.1	⊢■⊣	1.8 (1.0, 2.7)	≤18.4 mL/kg/min	74/67	1.5	-0.1	⊢■→	1.6 (0.6, 2.5)
≥30 kg/m²	45/46	1.4	-0.2	┝──■──┤	1.6 (0.3, 2.8)	>18.4 mL/kg/min	68/73	2.0	0.1	⊢■⊣	1.9 (1.0, 2.9)
Baseline Median LVEF						Baseline Beta-Blocker Use					
≤75.6%	73/68	1.9	0.0	⊢ ∎	1.8 (0.8, 2.8)	Yes	86/87	1.4	-0.2	⊢■⊣	1.6 (0.7, 2.5)
>75.6%	69/72	1.7	0.0	├─ ₩─┤	1.6 (0.6, 2.6)	No	56/53	2.2	0.2	⊢■→	1.9 (0.8, 3.1)
Baseline NYHA FC						Baseline Resting LVOT (mediar	ר)				
Class II	108/106	2.0	0.3	┝╼═╾┥	1.7 (0.9, 2.5)	≤51.1 mmHg	72/69	1.8	0.5	⊢■→	1.3 (0.3, 2.3)
Class III /IV	34/34	1.0	-0.9	⊢	1.9 (0.5, 3.3)	>51.1 mmHg	70/71	1.7	-0.4	⊢-∎1	2.1 (1.2, 3.1)
Baseline Median KCCQ-C	SS					Genotype					
≤78.1	67/75	1.7	-0.1	⊢∎⊸∣	1.8 (0.8, 2.8)	Positive	20/22	1.6	-1.0	⊢	2.6 (0.9, 4.2)
>78.1	75/65	1.8	0.1	⊢-■	1.7 (0.7, 2.6)	Negative	71/70	1.4	-0.1	⊢■→	1.4 (0.5, 2.3)
Interaction <i>P</i> values were >0.05 for	r all prespecified su	ibgroups	Favors Placebo	Favors	Treatment			-	Favors Placebo	Favors T	reatment

SEQUOIA-HCM: Secondary Endpoints




Statistically significant improvements in all 10 pre-specified secondary endpoints

Endpoints	P value
Primary Endpoint	
pVO ₂ change from baseline to Week 24	<0.0001
Secondary Endpoints	
1. KCCQ-CSS change from baseline to Week 24	<0.0001
2. NYHA Class Improvement by at least 1 class at Week 24	<0.0001
3. Valsalva LVOT-G change from baseline to Week 24	<0.0001
4. % Valsalva LVOT-G <30 mmHg at Week 24	<0.0001
5. Duration of SRT Eligible during 24 Weeks of Treatment	<0.0001
6. KCCQ-CSS change from baseline to Week 12	<0.0001
7. NYHA Class Improvement by at least 1 class at Week 12	<0.0001
8. Valsalva LVOT-G change from baseline to Week 12	<0.0001
9. % Valsalva LVOT-G <30 mmHg at Week 12	<0.0001
10. Total workload change from baseline to Week 24	<0.0001





Significant improvement in post-Valsalva left ventricular outflow tract gradient (LVOT-G)




--- Placebo Washout

Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established. Error bars are 95% CI Maron M. "Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy". ESC Heart Failure 2024.

Cytokinetics[®]

SEQUOIA-HCM: Secondary & Exploratory Endpoints



Maron M. "Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy". ESC Heart Failure 2024.

SEQUOIA-HCM: Responder Analysis



Significant improvement in exercise capacity and symptoms in composite responder endpoint

	<i>Aficamten</i> n=142	Placebo n=140
 ≥1.5 mL/kg/min increase in pVO₂ and ≥1 NYHA FC improvement or ≥3.0 mL/kg/min increase in pVO₂ and no worsening of NYHA FC, n (%) 	60 (42)	19 (14)
\geq 1.5 mL/kg/min increase in pVO ₂ and \geq 1 NYHA class improvement	44 (31)	9 (6)
\geq 3.0 mL/kg/min increase in pVO ₂ and no worsening of NYHA class	37 (26)	13 (9)
Both \geq 3.0 mL/kg/min increase in pVO ₂ and \geq 1 NYHA class improvement	21 (15)	3 (2)
Common rate difference vs placebo (95% Cl) <i>P</i> value	28 (18.8, <0.0	38.6)



SEQUOIA-HCM: Safety Data



AEs with ≥5% incidence

.....

There were no serious adverse cardiovascular events associated with *aficamten* treatment in SEQUOIA-HCM

Event, n (%)	Placebo (n=140)	<i>Aficamten</i> (n=142)
Overall AEs	99 (70.7)	105 (73.9)
Headache	10 (7.1)	11 (7.7)
Hypertension	3 (2.1)	11 (7.7)
Palpitations	4 (2.9)	10 (7.0)
Upper respiratory infection	12 (8.6)	9 (6.3)
COVID-19	9 (6.4)	8 (5.6)
Dyspnea	8 (5.7)	8 (5.6)
SAEs	13 (9.3)	8 (5.6)
Cardiac AEs	21 (15.0)	24 (16.9)
Discontinuations	4 (2.9)	5 (3.5)
New-onset AF	1 (0.7)	1 (0.7)
Appropriate ICD shock	1 (0.7)	0
LVEF <50% by core laboratory ^a	1 (0.7)	5 (3.5)
Dose reduction based on site-read LVEF <50%	1 (0.7)	7 (4.9)

^a1 placebo- and 1 aficamten-treated patient overlap with dose reduction based on site-read LVEF <50%.

Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established. AE, adverse event; SAE, serious adverse event.


Coats CJ. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy. ESC Heart Failure 2024.



SEQUOIA-HCM: Change in LVEF




Modest reduction in LVEF in patients on *aficamten* resulted in large reductions in LVOT-G



Mean Change in Core Laboratory LVEF Over 24 Weeks

Distribution of Categorical Changes in Core Laboratory LVEF from Baseline to Week 24




Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established. Coats CJ. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy. ESC Heart Failure 2024.



SEQUOIA-HCM: Low Incidence of LVEF <50%



5 (3.5%) of patients on *aficamten* had LVEF <50% determined by the core laboratory



a COVID-19 infection preceded LVEF <50% based on both core and site laboratory assessments. b Did not undergo dose adjustment (3.5%)

Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established. Coats CJ. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy. ESC Heart Failure 2024.



- **No heart failure** was experienced by any *aficamten*-treated patient with LVEF <50% by either core laboratory or site interpreted
- All *aficamten* patients with LVEF <50% were reversible



SEQUOIA-HCM: Low Overall Incidence of LVEF <50%



Core lab LVEF was prespecified source for statistical analyses

LVEF <50% assessed at 3.5% by core lab and 4.9% by site


Prespecified Analysis Core Lab Only	Age, y, Sex	<i>Aficamten</i> Dose, mg/d	BL Core LVEF, %	Study Week With Lowest Core LVEF	Lowest Core LVEF %	Matching Site LVEF %	NYHA Class	KCCQ-CSS	NT-proBNP, Change from BL, ng/dL	Down- Titration, mg	Next Visit LVEF Core	Matching Site LVEF %
LVEF <50%	30 M	20	65	8	48	62	1	+21	-535	N/A	56	65
4 <i>aficamten</i> patients	57 F	5	56	24	46	60	2	+14	-372	N/A	51	NR
	72 F	15	80	20	48	52	1	+5	-403	N/A	52	51
	57 F	20	84	16	43	59	1	+12	-921	N/A	72	68
Both Core & Site-												
Read LVEF <50%	75 F	Placebo	53	6	48	45	3	+29	-291	N/A	50	51
	72 F *	15	63	16	34	49	2	+14	111	15 to 10	55	51
1 <i>aficamten</i> patient 1 placebo patient												
	Age, y, Sex	<i>Aficamten</i> Dose, mg/d	BL Core LVEF, %	Study Week With Lowest Site LVEF	Lowest Site LVEF %	Matching Core LVEF %	NYHA Class	KCCQ-CSS	NT-proBNP, Change from BL, ng/dL	Down- Titration, mg	Next Visit LVEF Core	Matching Site LVEF %
	41 M	20	70	16	47	59	2	+2	-1597	20 to 15	54	50
Site-Read Only	52 M	20	69	16	46	51	1	+25	-712	20 to 15	60	50
LVEF <50%	76 F	15	87	16	48	53	3	+22	-44	15 to 10	52	50
6 <i>aficamten</i> patients	59 M	15	77	12	48	70	2	+10	-1482	15 to 10	60	55
	54 M	15	76	8	49	72	1	+31	-162	15 to 10	60	54
	66 M	20	76	20	45	53	3	+8	-83	20 to 15	61	60

* COVID-19 infection preceded LVEF <50% based on both core and site laboratory assessments.

NR = not recorded, site LVEF were not obtained following Week 24 per protocol

Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established. Coats CJ. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy. ESC Heart Failure 2024.

Implementation of Dosing in Real-World Setting (FOREST-HCM) Low incidence of LVEF <50% in patients with oHCM treated with *aficamten*



Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.

SEQUOIA-HCM Source: Coats CJ. Dosing and Safety Profile of *Aficamten* in Symptomatic Obstructive Hypertrophic Cardiomyopathy. ESC Heart Failure 2024. FOREST-HCM Source: Data on file – data cut 15 Apr 24

Cytokinetics[®]

SEQUOIA-HCM: Conclusions



Trial underscores potential clinical efficacy & safety of *aficamten* in patients with symptomatic oHCM

- Patients treated with *aficamten* observed to have:
 - Clinically meaningful improvements in exercise capacity (pVO₂), consistent across all prespecified subgroups
 - **Significant reduction in the burden of limiting symptoms** based on improvement in KCCQ-CSS and NYHA Functional Class
- *Aficamten* was generally well-tolerated with low frequency of LVEF <50%, all asymptomatic, with no treatment interruptions and no instances of worsening HF
- Functional & symptomatic improvements associated with benefits as early as 2 weeks; remained consistent & durable throughout treatment period:
 - Substantial relief from resting and provocable LVOT obstruction observed
 - Large reductions in cardiac biomarker NT-proBNP observed
 - Considerable reduction in the number of patients eligible for SRT observed
- Treatment effects were reversible within the 4-week washout period

Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established. Maron M. "*Aficamten* for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy". ESC Heart Failure 2024. Coats CJ. Dosing and Safety Profile of *Aficamten* in Symptomatic Obstructive Hypertrophic Cardiomyopathy. ESC Heart Failure 2024. Lewis G. Enhancing Exercise Response in Obstructive Hypertrophic Cardiomyopathy. ESC Heart Failure 2024.



The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

M.S. Maron, A. Masri, M.E. Nassif, R. Barriales-Villa, M. Arad, N. Cardim,
L. Choudhury, B. Claggett, C.J. Coats, H.-D. Düngen, P. Garcia-Pavia, A.A. Hagège,
J.L. Januzzi, M.M.Y. Lee, G.D. Lewis, C.-S. Ma, M. Michels, I. Olivotto, A. Oreziak,
A.T. Owens, J.A. Spertus, S.D. Solomon, J. Tfelt-Hansen, M. van Sinttruije,
J. Veselka, H. Watkins, D.L. Jacoby, S.B. Heitner, S. Kupfer, F.I. Malik, L. Meng,
A. Wohltman, and T.P. Abraham, for the SEQUOIA-HCM Investigators*



Preparing for Regulatory Submissions to FDA, EMA




- Participated in two meetings with FDA in Q1 2024
- **Type B meeting with FDA** to occur in Q2 2024
- Meetings with EMA in Q2 2024
- Expect to submit NDA to FDA in Q3 2024 and MAA to EMA in Q4 2024: development of all modules underway and manufacturing activities on track

Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.



Aspirational Profile of Aficamten & Results from SEQUOIA-HCM Inform Potential Risk Mitigation





Few Dose Reductions Occurred During Maintenance FOREST-HCM data cut as of September 15, 2023




Dose Titration Phase

- No treatment-related LVEF <50% during the titration period
- Of the 94 patients having completed the titration period, ~2/3 are receiving 15 and 20 mg qd
- Approximately 30% of patients have reduced doses or discontinued background therapy at the discretion of the treating physician and/or request from the patient

Maintenance Phase

- 579 monitoring echocardiograms completed* in oHCM patients
- None with LVEF <40% requiring treatment interruption
- 3 patients (0.5%) with LVEF <50%
 - Two asymptomatic patients (LVEF of 47% and 49%) resulting in per-protocol dose reduction
 - One patient with atrial fibrillation (unrelated) and LVEF of 47%
 - All 3 patients are currently receiving *aficamten* with apparent relief from obstruction, symptoms & improved biomarkers



Target dose defined as achieved if Valsalva LVOT-G ≤ 30 mmHg or no dose change for 2 consecutive visits

Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.




MAPLE-HCM: Phase 3 Monotherapy Trial



Active-comparator trial of *aficamten* as monotherapy vs. *metoprolol* in patients with oHCM

- Trial to enroll approximately
 170 patients
- Primary endpoint: change in peak VO₂, assessed by CPET from baseline to Week 24
- Secondary endpoints: change in NYHA class, KCCQ, NT-proBNP, and measures of structural remodeling



Cvtokinetics

ACACIA-HCM: Pivotal Phase 3 Trial in nHCM Currently enrolling

- Trial to enroll approximately 420 symptomatic nHCM patients
- Primary endpoint: change in KCCQ Clinical Summary Score from baseline to Week 36
- **5-20 mg doses**; 6-week titration period
- Secondary endpoints:
 - Change in pVO₂, Ve/VCO₂,
 - Left atrial volume index (LAVI)
 - NT-proBNP
 - Proportion of patients with ≥1 class improvement in NYHA from baseline to Week 36
 - Time to first cardiovascular event

^a Part 1: All participants followed until week 36


^b Part 2: Participants completing Week 36 continue until either Week 72 (followed by EOS at Week 76) OR the last randomized participant in Part 1 completes Week 36.

^c Site-read focused echocardiogram for titration visit (sole criterion). *Aficamten* dose range 5-20 mg.

^d 4-week follow up after last dose

Cvtokinetics

Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.






CEDAR-HCM: Clinical Trial in Pediatric Population **Currently enrolling**



- Expected to enroll initial cohort of ~40 adolescent patients aged 12 to 17
- Data from adolescent patients will support decision to enroll cohort of ~8 to 10 patients aged 6 to 11
- **5-20 mg doses**; 6-week titration period
- Primary endpoint: change in **LVOT-G** from baseline to Week 12
- Secondary endpoints: change in resting LVOT-G, NYHA Functional Class, pharmacokinetics & cardiac biomarkers



Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.

a Up-titration to the next dose in Period 1 will be managed by the IRT system and will only occur if Valsalva LVOT-G is > 30 mmHg and biplane LVEF is > 55% b In Period 2, participants will start dosing with aficamten at the lowest dose (5 mg) and up-titration to the next dose (10, 15, or 20 mg) will be managed by the Principal Investigator or designee if Valsalva LVOT-G is > 30 mmHg and biplane LVEF is > 55%. c Additional ad hoc titrations after Week 20 may occur at ad hoc titration visits (at least 2 weeks apart) or during a planned visit (ie, Weeks 26, 38, 50, or 62). A titration follow-up visit is required 2 weeks after any titration occurring after Week 20

e Intensive PK substudy may occur at Week 8 or Week 12



d Focused echocardiogram (LVOT-G and LVEF only)


Cytokinetics Poised to Compete in the Specialty Cardiology Business

Potential for high return on investment

	Broad Cardiology	Specialty Cardiology
Example Therapies	Heart failure, cholesterol, blood thinner	HCM, TTR amyloidosis
Prescribers	Broad: Cardiologists, PCPs (50K+)	Concentrated: Subset of cardiologists (~10K)
ROI / Prescriber	Limited	High
Distribution	Retail	Limited, specialty distributor
Customer-Facing Reps	Entry level	Highly experienced
Support Services	Standard: Affordability / copay	High-touch: Financial, education, journey
Managed Care	Competitive/high rebates	Managed to label
Diagnosis	High awareness and diagnosis rate	Limited awareness with high % undiagnosed
HCP – Rep Interactions	Brief features/benefits	Comprehensive broad-based discussion



oHCM CMI Preference Shares in Eligible Patient Population*




- Potential target product profile for *aficamten* interest creates **share opportunity** in newly treated CMI patients
- Aficamten could also be expected to expand the total CMI market
- Key attributes that may drive preference include the potential for:
 - LVOT gradient reduction
 - Change in NYHA Functional Class
 - Pharmacodynamics/LVEF maintenance
 - Change in KCCQ
 - Absence of DDI

Survey results are based on the aspirational profile of aficamten and if approved, the actual profile could vary materially.

Source: *Aficamten* Impact of Product Attributes on Product Preference Share n=443 cardiologists, Quantitative research including conjoint - Cogent *Aficamten* is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.



If *Aficamten* is Approved, Expect Majority of CMI-Eligible Patients Available at Launch **Diagnosis of HCM anticipated to grow 5x the rate of the general U.S. population**




1. DoF: SHA; Symphony PTD (Patient Transaction Data): Includes patients diagnosed since 2016 and having any HC transaction in the claims data universe in the last year June 2022-May 2023);

2. Butzner et al 2021 estimated a 8% growth rate in diagnosed HCM patients between 2013-2019 <u>https://www.ajconline.org/article/S0002-9149(21)00783-9/fulltext;</u> CYTK is forecasting an average growth rate of 5% over the coming decade; 3. Internal forecasts

Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established. Projections and forecasts for illustration

Cardiologists Located in Concentrated Geographic Clusters Across the US ~75% of the HCM patient volume is treated by ~10,000 cardiologists

Geographic Distribution of HCM Patients




HCM Patient Concentration by Cardiologist

Note: includes only patients who are treated by a cardiologist - not all patients see a cardiologist; sample of 67K HCM patients Source: Symphony PTD (Patient Transaction Data); mapping of HCPs to HCOs using Definitive Healthcare Data 2023 and 7/2023 mapping; Patient volume by dominant Cardiologist Location 7/2023 Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.



Gated Build of Commercial Infrastructure Majority of spending to occur closer to potential approval in 2025

2/3 of hiring to occur at-approval






Continued insight generation Market access strategy validation Pricing strategy finalization Distribution approach Payer engagement Brand strategy evolution Customer account identification Launch campaign development Customer Experience Payer Pre-approval Information Exchange Sales force planning Data & Technology Infrastructure build Omnichannel execution Market development rollout

Initiated upon FDA approval Media purchases Patient support programs Peer to peer engagement HCP Omnichannel launched

US Commercial Readiness Milestones for *Aficamten* 2024-2025



Omecamtiv Mecarbil




Omecamtiv mecarbil is an investigational agent and has not been approved for use by the U.S. Food & Drug Administration (FDA) or any regulatory agency. The safety and effectiveness of this product has not been established.


Omecamtiv Mecarbil: Mechanism of Action

Omecamtiv mecarbil shifted equilibrium in favor of the pre-powerstroke state

"More hands pulling on the rope"




Pre-Powerstroke State



Before Omecamtiv Mecarbil

After Omecamtiv Mecarbil



Malik, et al. Science 2011; 1439-1443 Planelles-Herrero, et al. Nature Comm 2017; 1-10 Shen et al, Circ HF, July 2010, 522-527 Teerlink, et al. JACC-HF 2020; 329-340 Omecamtiv mecarbil is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.



Omecamtiv Mecarbil: Potential for High-risk Severe HF Patients Despite GDMT

Advancing efficient, pragmatic Phase 3 clinical trial

High Unmet Need

The large and growing heart failure population faces frequent hospitalizations, high mortality rates, comorbidities, and challenges staying on GDMT. Despite SGLT2 inhibitors, patients remain at significant risk.

Market Opportunity

18% of 7.1M patients with HFrEF have worsening heart failure (LVEF< <30%)

Estimated 8+ years of market exclusivity

The NEW ENGLAND JOURNAL of MEDICINE

IANUARY 14, 202

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

J.R. Teerlink, R. Diaz, G.M. Felker, J.J.V. McMurray, M. Metra, S.D. Solomon, K.F. Adams, I. Anand, A. Arias-Mendeaz, T. Bitengi Saensen, M. Böhrn, D. Bonderman, J.G.F. Cleland, R. Corbalan, M.G. Crespo-Leiro, U. Dahlsttöm, L.E. Echeverrai, J.C. Fang, G. Filippate, C. Conscez, E. Gonalessova, A.R. Goudev, J.G. Howlett, S.E. Lanfear, J. Li, M. Lund, P. Macdonald, V. Mareev, S. Momomura, E. O'Meara, A. Parkhomenko, P. Ponikowski, F.J.A. Ramires, P. Serptisk, S. Klawa, J. Spinar, T.M. Suter, J. Tomcasniy, H. Vandekerchove, D. Vincreanu, A.A. Voors, M.B. Yilmaz, F. Zannad, L. Sharpaten, J.C. Legg, C. Varin, N. Honarpour, S.A. Abbasi, F.I. Malik, and C.E. Kurtz, for the CALACTIC-H Finvestigators*

ABSTRACT

SROUND

The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. grees, and affiliations are listed in the Ap pendix. Address reprint requests to D Its effect on cardiovascular outcomes is unknown 203. Rm. 2A-49. 4150 Cl We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive mecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or ided in the Supple wailable at NEIM.org urgent visit for heart failure) or death from cardiovascular causes. 13, 2020, at NEJM.org. During a median of 21.8 months, a primary-outcome event occurred in 1523 of N Engl J Med 2021;384:105-16 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 pa- DOI: 10.1056/NEIM002022 tients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P=0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Ouestionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups.

Among patients with heart failure and a reduced ejection, those who received one-cantive meacrabil had a lower insidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Angen and others; GALACITC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-02299-28.)

Ph 3 clinical trial results in 8,000 patients point to important treatment benefit

Planning confirmatory Ph 3 trial, **n=~2,000, 2-3 years** to completion

Primary endpoint: time to CV death, HF events, transplant/LVAD, or stroke

Larger treatment benefit in patients with lower LVEF and other markers of advanced HF


Pragmatic design elements including EHR screening, limited monitoring visits, remove visits, and limited safety labs & AE reporting



GALACTIC-HF: Clinical Trial Overview Phase 3 clinical trial




Event-driven clinical trial; 8,256 patients randomized in 35 countries at 944 clinical trial sites





Primary Composite Endpoint






Time to first HF event or CV death



Benefit Observed to Increase as Baseline LVEF Decreased



ARR = Absolute Risk Reduction. RRR = Relative Risk Reduction.

Teerlink JR, Diaz R, Felker GM, et al. Effect of Ejection Fraction on Clinical Outcomes in Patients treated with Omecamtiv Mecarbil in GALACTIC-HF. JACC. 2021 Omecamtiv mecarbil is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.

Cytokinetics[®]



Large Treatment Effect in Easily Defined HF Population

	N	Hazard Ratio (95% CI)	Nom p-value	ARR
All Patients	8232	⊢		0.025	2.1
LVEF <30%	4704	F		<0.001	4.9
+ Hosp <3 mos	2836	F1		<0.001	6.2
+ SBP <110	1881	F		0.004	7.2
+ Class III/IV	2249	⊢I		<0.001	8.9
+ NT-proBNP ≥1000 pg/mL	2852	⊢−−−− 1		<0.001	8.8
	0.6	0.7 0.8 0.9 Omecamtiv mecarbil	1 1.1 1.2 Placebo		





Treatment Effect in High-Risk Population with LVEF <30%

LVEF < 30% NTproBNP ≥ 1000 pg/mL Hospitalization within <u>12 mo</u>	N	HR (95% CI)	Placebo Event Rate (%)	ARR (/100 p-y)	p-value
<u>Primary Composite Endpoint</u> (CV death, HF event, LVAD/transplant, stroke)		0.78 (0.70, 0.86)	49.4	8.8	p < 0.001
CV Death	2852	0.87 (0.75, 1.01)	25.5	1.8	p = 0.07
First HF Event		0.75 (0.66, 0.85)	38.1	7.5	p < 0.001


LVAD = left ventricular assist device, ARR = absolute risk reduction



Residual Risk is High Despite Best Therapy DAPA-HF Trial: Patients on GDMT including SGLT2-i

DAPA-HF trial (dapagliflozin group)

- Primary endpoint: CV Death/HF hospitalization/urgent HF visit
- 4744 patients
- Renin-angiotensin system blocker **94%**
- Beta-clocker 96%
- Mineralocorticoid receptor (aldosterone) antagonist **71%**



McMurray J et al, N Engl J Med. 2019;381:1995-2008




Residual Risk is High Despite Best Therapy

DAPA-HF trial (dapagliflozin group)

- 2373 patients
- Median follow-up 18.2 months
- Renin-angiotensin system blocker 94%
- Beta-blocker 96%
- Mineralocorticoid receptor (aldosterone) antagonist 71%
- SGLT2 inhibitor 100%

Event rate according to LVEF (<30% vs. ≥30%)





Safety in Low LVEF Subgroup Consistent with Overall Population




Incidences of SAEs, ventricular arrhythmias, & cardiac ischemic events were similar	Overall P	opulation	LVEF	≤28%
Incidence of stroke was lower with <i>omecamtiv mecarbil</i>	Omecamtiv Mecarbil N=4110 %	Placebo N=4101 %	Omecamtiv Mecarbil N=2208 %	Placebo N=2236 %
Serious adverse events	57.7	59.4	58.8	61.9
Adverse events				
Ventricular tachyarrhythmia (narrow SMQ)	7.1	7.4	8.0	8.2
Torsade de pointes/QT prolongation (SMQ)	4.3	4.8	5.2	5.8
Serious adverse ventricular arrhythmia requiring R	2.9	3.1	3.4	3.6
Adjudicated major cardiac ischemic event	4.9	4.6	4.6	4.2
Myocardial infarction	3.0	2.9	3.0	2.9
Hospitalized for unstable angina	0.6	0.3	0.4	0.2
Coronary revascularization	2.8	2.9	2.6	2.5
Adjudicated stroke	1.6	2.8	2.1	2.6

GALACTIC-HF CSR Table 14.3.4.5.27




Phase 3 Confirmatory Anticipated Clinical Trial Design Trial design to be finalized


- Primary endpoint: time to CV death, HF events, transplant/LVAD, or stroke
- Enriched dosing for adherence, with OM run-in period. Plan to randomize only those expected to land in therapeutic range
- Pragmatic design elements:
 - EHR screening
 - Limit monitoring visits
 - Remote visits
 - Limited safety labs & AE reporting





Omecamtiv Mecarbil: HFrEF Epidemiology






Circ Heart Fail. 2012;5:720-726 REAL HFrEF Study 2021

Omecamtiv mecarbil is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.

Cytokinetics[®]

Omecantiv Mecarbil: SOC Not Addressing Needs of Patients with EF <30%










CK-586 is an investigational agent and has not been approved for use by the U.S. Food & Drug Administration (FDA) or any regulatory agency. The safety and effectiveness of this product has not been established.


CK-586: Distinct Mechanism of Action from Aficamten





Heart Failure with Preserved Ejection Fraction (HFpEF)

Despite broad use of standard treatments and advances in care, the prognosis for patients with heart failure is poor¹



1. Jhund PS, MacIntyre K, Simpson CR, et al. Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003. Circulation. 2009;119:515-523.

 Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, Fonarow GC, Heidenreich P, Ho JE, Hsich E, İbrahim NE, Jones LM, Khan SS, Khazanie P, Koelling T, Krumholz HM, Khush KK, Lee C, Morris AA, Page RL 2nd, Pandey A, Piano MR, Stehlik J, Stevenson LW, Teerlink JR, Vaduganathan M, Ziaeian B; Writing Committee Members. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. J Card Fail. 2023 Oct;29(10):1412-1451. doi: 10.1016/j.cardfail.2023.07.006. Epub 2023 Sep 26. PMID: 37797885; PMCID: PMC10864030.


3. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012 Nov;5(6):720-6. doi: 10.1161/CIRCHEARTFAILURE.111.966366. Epub 2012 Aug 30. PMID: 22936826; PMCID: PMC3661289.

4. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-e327.



CK-586: Shallow In Vivo Concentration-Response

CK-586 will have a shorter half-life in humans than aficamten




Pharmacodynamic window Fractional shortening IC ₅₀ /IC ₁₀ ratio			
mavacamten	2.8x		
aficamten	9.9x		
CK-586	9.3x		

 IC_{10} : plasma concentration at 10% relative reduction in fractional shortening IC_{50} : plasma concentration at 50% relative reduction in fractional shortening

Compound half-life in humans	Actual	Predicted
aficamten	~3 days	2.8 days
CK-586	~15 hours	15 hours

CK-586 is Efficacious in ZSF1 Obese Rat Model of HFpEF Model is representative of hypertensive, diabetic, metabolic aspects of HFpEF

10 weeks of treatment improved diastolic function and reduced cardiac fibrosis





Phase 1 Data Support Advancement to Phase 2 Clinical Trial Full data to be presented at a medical congress in 2H 2024

Phase 1 Design	Key Findings
 7 SAD cohorts (10 mg to 600 mg) comprised of 10 participants each 2 MAD cohorts (100 and 200 mg once daily) comprised of 10 participants each 	 Pharmacodynamics were evaluated using echocardiography and consistent with expectations CK-586 was generally safe and well-tolerated with linear PK No serious adverse events were observed Stopping criteria were not met








CK-136 is an investigational agent and has not been approved for use by the U.S. Food & Drug Administration (FDA) or any regulatory agency. The safety and effectiveness of this product has not been established.

CK-136: Mechanism of Action

Key biochemical and cellular features

The first selective cardiac troponin activator




¹PD Window = Maximum Tolerated Concentration (MTC) / 10% increase in Fractional Shortening (FS)

CK-136: Exposure Response Relationship

Exposure-response of troponin activator is shallower than myosin activator

Completed Phase 1 study and have begun analyzing data

Animal Models of Cardiac Function




¹PD Window = Maximum Tolerated Concentration (MTC) / 10% increase in Fractional Shortening (FS)


Corporate Profile



Myosin Platform Drives Multiple Data Milestones and Potential Approvals



Equity Financing, Royalty Pharma Fundraising Well funded to enable our strategic priorities



Aficamten, omecamtiv mecarbil and CK-586 are investigational drugs and are not approved by any regulatory agency. Their safety and efficacy have not been established.



Structured Financing Transaction with Royalty Pharma Revenue sharing, royalty monetization, longer-term debt & equity investment

Four separate components providing \$250M upon closing; up to \$575M total

Broadens capital access to support prospective commercial launch and monetize myosin pipeline Aficamten Aficamten **Omecamtiv CK-586 CK-586** Mecarbil **\$50M Upfront Capital** Royalty Phase 2 Trial Funding **Phase 3 Trial Funding** for Future \$100M Upfront **Commercial Launch Capital to Fund Ph 3** \$50M Upfront Option to invest up Restructured to Trial **Capital to Fund Ph 2** to an additional 4.5% up to \$5B of PoC trial • Eligible for \$150M for **Ph 3** Positive Ph 3 and annual net sales additional \$175M development timely FDA approval • In exchange for 1.0% and 1% above \$5B, within 12 months of yield RP a 1.0x royalty on net sales compared to prior • If RP opts into Ph 3, it FDA approval for milestone payment of CK-586 4.5% up to \$1B and may receive up to oHCM and 2% royalty on 3.5% above \$1B 0.75x milestone and global sales Capital repayable 4.5% royalty on Otherwise. over 10 years in global sales Cytokinetics repays quarterly • If RP opts out of Ph 3 loan quarterly installments funding, it gets a 1% (2.275x-2.375x) over (totaling 1.9x) royalty on global net 18 or 22 quarters sales starting in 2028 or 2030

Royalty Pharma purchased \$50M of Cytokinetics' stock

Aficamten, omecamtiv mecarbil and CK-586 are investigational drugs and are not approved by any regulatory agency. Their safety and efficacy have not been established.



Royalty Pharma Agreement: Efficient Fundraising for Next Wave of Innovation

Omecamtiv Mecarbil

Cytokinetics received **\$100M** at a market-rate competitive cost of capital (low double-digit interest rate)

- Cost effective Ph 3 trial: \$100M covers costs
- Clinical trial designed to confirm results from prespecified sub-group in GALACTIC-HF
- Expected to start in Q4 2024



Estimated peak sales in U.S. market



Years of market opportunity in U.S. estimated

Highly Synergistic

Can leverage commercial infrastructure for *aficamten*



High Conviction

- RP made investment after having only seen Ph 1 data
- Initial investment covers entire Ph 2 POC trial
- RP has opt-in right to fund Ph 3 costs up to \$150M



CK-586 Investment

Cytokinetics received **\$50M** up-front and

is eligible to receive an additional \$150M

Shareholder Value

- RP entitled to 1% royalty on future net sales
- If opt-in is exercised, royalty rate increases to 4.5%
- RP receives 0.75x milestone upon approval



Balance Sheet & Financial Guidance

Approximately 2 years of cash runway based on 2024 guidance*

2024 Condensed Balance Sheet

As of 3/31/2024	in millions
///////////////////////////////////////	Total
Cash and investments	\$634.3
Accounts receivable	\$0.8
PPE	\$68.0
Leased assets	\$78.2
Other assets	\$26.8
Total Assets	\$808.1
Convertible Debt, net	\$549.8
Liability related to sale of future royalties	\$390.2
Lease liability	\$136.8
Other liabilities	\$127.4
Total Liabilities	\$1,204.2
Working capital	\$549.8
Accumulated deficit	(\$2,247.9)
Stockholders' deficit	(\$396.2)
Wtd Avg Basic Shares Outstanding (million)	101.9

2024 Financial Guidance

- GAAP Operating (R&D and G&A) Expense:
- Non-cash expenses included in GAAP Operating Expense**:
- Operating Expense (R&D and G&A) excluding non-cash expenses

\$535 to \$555 million





• Expected Net Cash Utilization***:




* Including up to \$175M we expect to be available to us under our loan agreement with Royalty Pharma, upon satisfaction of conditions.

Non-cash expenses included in GAAP Operating Expenses are comprised of stock-based compensation and depreciation. Non-cash expense is a non-GAAP financial measure that should be considered as supplemental information regarding our operations and should not be considered without also considering our results prepared in accordance with U.S. GAAP. It should not be considered as a substitute for, or superior to, our U.S. GAAP results. We believe non-cash expenses is a relevant and useful operational measure as our management uses it to budget and plan for the business and also useful to investors because similar measures are used by securities analysts, investors and others in their evaluation of companies in similar industries. Non-cash expense as we present it may not be comparable with similarly titled operational measures used by other companies. Our expectations regarding non-cash expenses are based on information currently available to us, but are forward-looking statements subject to change. *We define "Net Cash Utilization" as change in cash, cash equivalents and investments year over year.



Planned 2024 Milestones



Aficamten and CK-586 are investigational drugs and have not been approved. Their safety and efficacy have not been established.





thank you

Vi, diagnosed with HCM Avonne, diagnosed with HCM ohn, diagnosed with heart failure

©2024 CYTOKINETICS, All Rights Reserved. CYTOKINETICS® and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries Actual patients who consented to use of their name, image, and condition.